Routine

Chronic asthma — stepwise (maintenance) management (GINA track 1 MART / AIR; interval asthma)

chronic-asthma-stepwise · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Long-term control of asthma between attacks — distinct from the acute severe asthma entry. GINA 2024/2025 preferred pathway is Track 1: an ICS-formoterol inhaler used as reliever at every step, giving anti-inflammatory reliever (AIR) therapy at steps 1-2 and maintenance-and-reliever therapy (MART) from step 3. Aim: control symptoms, minimise future risk (exacerbations, fixed airflow limitation, medication side-effects). Never treat asthma with SABA alone.

Red flags

  • Frequent SABA use / SABA-only treatment (high mortality risk)
  • >=1 severe exacerbation or any ICU/ventilation in past year
  • Falling FEV1, declining peak-flow trend
  • Nocturnal symptoms, exercise limitation despite therapy
  • Poor adherence or inhaler technique masking as treatment failure
  • Features suggesting alternative/overlap diagnosis (weight loss, haemoptysis, clubbing, fixed obstruction)

Assessment

Differential diagnosis

  • COPD / asthma-COPD overlap
  • Inducible laryngeal obstruction (vocal cord dysfunction)
  • Bronchiectasis
  • Heart failure
  • ABPA
  • Eosinophilic granulomatosis with polyangiitis
  • Chronic cough syndromes (GORD, upper-airway cough)

Investigations

  • Confirm diagnosis objectively before long-term Rx: spirometry with reversibility (FEV1/FVC <0.7 with >=12% and >=200 mL post-bronchodilator improvement), or peak-flow variability, or bronchial challenge
  • FeNO where available (supports eosinophilic/type-2 inflammation)
  • Blood eosinophils, total IgE (consider ABPA if high)
  • Inhaler technique and adherence review at EVERY visit
  • Assess control: GINA symptom control (daytime symptoms >2/wk, night waking, reliever >2/wk, activity limitation)
  • Trigger/comorbidity screen: rhinosinusitis, GORD, obesity, OSA, smoking, occupational exposure, NSAID/aspirin sensitivity
  • CXR if diagnostic doubt or red flags

Management

  • Objectively confirm asthma before committing to long-term controllers
  • Adopt GINA Track 1 (ICS-formoterol reliever) wherever the device/formulation is available — avoids SABA-only treatment and simplifies regimens
  • Step 1-2: as-needed low-dose ICS-formoterol (budesonide-formoterol or beclometasone-formoterol)
  • Step 3: low-dose ICS-formoterol as MART (regular low-dose maintenance + same inhaler as reliever)
  • Step 4: medium-dose ICS-formoterol maintenance, continued as MART
  • Step 5: add LAMA (triple therapy); refer for phenotyping and consider a biologic (anti-IgE/anti-IL5/anti-IL4R) for severe type-2 asthma
  • Review in 2-3 months; step down after >=3 months of good control to lowest effective dose
  • Reinforce inhaler technique, adherence, smoking cessation, written personalised action plan, annual influenza vaccine
  • Check/record reliever overuse (>=3 canisters SABA/yr = high exacerbation risk)

Drugs & doses

Budesonide-formoterol 200/6 micrograms DPI (or 160/4.5 pMDI): 1 inhalation as needed (steps 1-2, AIR); for MART 1 inhalation BD + 1 as needed, max ~12 inhalations/day total — follow product label [verify local dose]
Beclometasone-formoterol 100/6 micrograms: as-needed reliever / MART per GINA Track 1 [verify local dose]
Tiotropium 5 micrograms (Respimat) once daily — add-on LAMA at step 5
Prednisolone 40 mg PO once daily for 5-7 days for exacerbations (short rescue course; not maintenance)
Montelukast 10 mg PO once daily at night — alternative/add-on controller (counsel re neuropsychiatric effects)
Biologics (specialist): omalizumab, mepolizumab, benralizumab, dupilumab for severe eosinophilic/allergic asthma [verify eligibility & dose]

Disposition

Primary care / respiratory outpatient management. Refer to respiratory clinic if step 4-5, difficult/severe asthma, diagnostic doubt, or >=1 severe exacerbation/year. Provide written action plan and arrange follow-up within 2-3 months of any change.

Complications & pitfalls

  • Life-threatening exacerbation
  • Fixed airflow limitation (airway remodelling)
  • Oral steroid toxicity (osteoporosis, diabetes, adrenal suppression)
  • ICS side-effects: oral candidiasis, dysphonia
  • Under-recognition of severe/difficult asthma
  • Growth effects in children (high-dose ICS)

Exam pearls

  • GINA 2024/2025 no longer recommends SABA-only treatment at any step — ICS-containing therapy for all (GINA Global Strategy 2024/2025).
  • Track 1 (ICS-formoterol reliever/MART) is preferred over Track 2 (SABA or ICS-SABA reliever) as it lowers exacerbation risk.
  • Only beclometasone-formoterol or budesonide-formoterol are licensed for MART — do NOT use salmeterol-containing ICS/LABA as a reliever.
  • Daily low-dose ICS is no longer advised at step 1 in GINA 2024/2025; use as-needed ICS-formoterol.
  • Always re-check adherence and technique before stepping up — most 'uncontrolled' asthma is untreated or mistreated, not refractory.
  • Blood eosinophils/FeNO help select biologic candidates at step 5.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.